+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antibody Drug Conjugate (ADC) Technology Market Industry Trends and Global Forecasts to 2035, by Generation of Technology, Type of Conjugation, Type of Linker, Type of Payment Model Adopted and Key Geographical Regions- Product Image
Antibody Drug Conjugate (ADC) Technology Market Industry Trends and Global Forecasts to 2035, by Generation of Technology, Type of Conjugation, Type of Linker, Type of Payment Model Adopted and Key Geographical Regions- Product Image
New

Antibody Drug Conjugate (ADC) Technology Market Industry Trends and Global Forecasts to 2035, by Generation of Technology, Type of Conjugation, Type of Linker, Type of Payment Model Adopted and Key Geographical Regions

  • PDF Icon

    Report

  • 407 Pages
  • March 2025
  • Region: Global
  • Roots Analysis
  • ID: 5852451
Description Jump to:

The global ADC technology market is estimated to grow from USD 1.18 billion in 2025, to USD 4.37 billion by 2035, at a CAGR of 11.5% during the forecast period, till 2035.

ADC Technology Market (Focus on ADC Linker & ADC Conjugation Technologies): Growth and Trends

Antibody drug conjugate has emerged as a versatile anti-cancer therapy that has been proven to be more effective and less toxic to patients. Such interventions are designed to identify specific antigens that are expressed on the surface of cancer (target) cells so that the effects of the cytotoxin / drug are focused on the elimination of only the cancerous cells. Over the past few years, more than 20 ADC therapies have been approved by various regulatory agencies. Moreover, over 350 drug therapies are being evaluated in clinical trials across the globe. This demonstrates the extensive development initiatives that are being undertaken by stakeholders in this domain. However, the complex design and structure of ADCs present a significant challenge to the overall tolerability and efficacy of the molecule. Thus, more advanced ADC technology is required to generate the controlled assembly of ADCs while maintaining tolerability and safety profiles. It is worth highlighting that significant investments have been made in the ADC technology market in order to meet the growing demand for antibody drug conjugates. As drug developers invest more in these innovative therapies, the market for ADC technology is likely to witness substantial market growth during the forecast period.

ADC Technology Market (Focus on ADC Linker & ADC Conjugation Technologies): Key Insights

The report delves into the current state of the ADC technology market and identifies potential growth opportunities within the industry.

Some key findings from the report include:

  • At present, over 95 ADC linker and conjugation technologies are being offered by various technology developers across the globe; around 55% of these are third-generation technologies.
  • The current market landscape is highly fragmented, featuring the presence of both new entrants and well-established players across key geographical regions.
  • Over 2,100 patents have been filed / granted for ADC linker and conjugation technologies, by industry and non-industry players, to protect the intellectual property generated within this field.
  • To cater to the increasing demand for homogenous ADC therapies, a number of players have stepped up to introduce technologically advanced platforms and establish a strong brand position in this industry.
  • A considerable increase in partnership activity has been witnessed in this domain; ~70% of the deals were related to licensing of technologies, primarily focused on product development and R&D purposes.
  • ADC drug developers are anticipated to continue to form strategic alliances with ADC linker and conjugation technology providers to further strengthen their respective technology portfolios.
  • Stakeholders have adopted different business models to maximize the gain from ADC technologies; a considerable number of players have signed multiple partnerships to out-license their technologies.
  • In pursuit of gaining a competitive edge, stakeholders are actively enhancing their existing capabilities to improve their respective technology portfolios and compliance with evolving industry standards.
  • At present, over 350 ADC therapeutic candidates are undergoing clinical trials for the treatment of various oncological disorders; majority of these ADCs are being evaluated as monotherapies.
  • With the growing focus on development of efficacious and site-selective drugs, the ADCs linker and conjugation technologies market is anticipated to witness an annualized growth of ~15%, over the next decade.
  • The estimated market opportunity is projected to be well distributed across different types of linkers and key geographical regions.

Report Segmentation

Generation of Technology

  • Third-Generation
  • Second-Generation
  • Next-Generation

Type of Conjugation

  • Chemical
  • Chemoenzymatic
  • Enzymatic

Type of Linker

  • Cleavable
  • Non-cleavable

Type of Payment Model Adopted

  • Upfront Payments
  • Milestone Payments

Key Geographical Regions

  • North America
  • Europe
  • Asia-Pacific and Rest of the World

ADC Technology Market (Focus on ADC Linker & ADC Conjugation Technologies): Key Segments

Third-Generation Technologies are Likely to Dominate the ADC Technology Market During the Forecast Period

Based on the generation of technology, the market is segmented into second-generation, third-generation and next-generation. It is worth highlighting that majority of the current ADC technology market is captured by third-generation technologies and this trend is likely to remain the same in the forthcoming years.

Currently, Chemical Conjugation Segment Occupies the Largest Share of the ADC Technology Market

Based on the type of conjugation, the market is segmented into chemical, chemoenzymatic and enzymatic. The current market is expected to be driven by chemical conjugators. It is worth highlighting that the chemoenzymatic segment is likely to grow at a relatively higher CAGR, during the forecast period.

Cleavable Segment is Likely to Capture the Largest Share of the ADC Technology Market During the Forecast Period

Based on the type of linker, the market is segmented into cleavable and non-cleavable. It is worth highlighting that majority of the current ADC technology market is captured by cleavable linkers and this trend is unlikely to change in the mid-long term.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, and Asia-Pacific and Rest of the World. A significant proportion of the market is expected to be captured by North America and Europe. It is worth highlighting that, over the years, the market in Asia-Pacific and Rest of the World is expected to grow at a higher CAGR.

Sample Players in the ADC Technology Market Profiled in the Report Include:

  • Alteogen
  • Ambrx
  • Antikor
  • Catalent Biologics
  • Heidelberg Pharma
  • Iksuda Therapeutics
  • LegoChem Biosciences
  • Mersana Therapeutics
  • NBE-Therapeutics
  • Seattle Genetics
  • Sutro Biopharma

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

  • Scientist, Abzena
  • Chief Scientific Officer, MedLink Therapeutics
  • Head of Business Development, Merck KGaA
  • Board Member, Singzyme
  • General Manager, Research and Development, Director of ADC Process Development, Ajinomoto
  • Head of Research, Eucodis Bioscience
  • Former Chief Business Officer, NBE-Therapeutics
  • Chief Executive Officer, Shanghai Miracogen
  • Chief Scientific Officer, Synaffix

ADC Technology Market (Focus on ADC Linker & ADC Conjugation Technologies): Research Coverage

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the ADC linker and antibody conjugation technologies, focusing on key market segments, including [A] generation of technology, [B] type of conjugation, [C] type of linker, [D] type of payment model adopted and [E] key geographical regions.
  • Market Landscape: A comprehensive evaluation of ADC linker and conjugation technologies, considering various parameters, such as [A] type of technology, [B] availability of licensing, [C] generation of ADC technology, [D] site specificity, [E] type of conjugation, [F] drug antibody ratio, [G] compatible linker, [H] conjugation chemistry, [I] conjugation site, [J] type of linker. It also includes information on ADC linker and antibody conjugation technology companies, based on several parameters, such as their [K] year of establishment, [L] company size (based on number of employees) and [M] location of headquarters.
  • Technology Competitiveness Analysis: A comprehensive competitive analysis of ADC linker and conjugation technologies, examining factors, such as portfolio strength, technology competitiveness and partnership activity (in terms of number of partnerships). The analysis was designed to enable stakeholder companies to assess their existing capabilities and identify opportunities to achieve a competitive edge in the industry.
  • Company Profiles: In-depth profiles of key industry players engaged in the development of ADC linker and ADC conjugation technologies, focusing on [A] company overviews, [B] technology portfolio, [C] insightful recent developments and [D] an informed future outlook.
  • Patent Analysis: Detailed analysis of various patents filed / granted related to ADC linker and ADC conjugation technologies based on [A] type of patent, [B] publication year, [C] application year, [D] number of granted patents and patent applications, [E] patent jurisdiction, [F] focus area, [G] CPC symbols, [H] patent age, [I] type of applicant (on the basis of number of patents), and [J] individual patent assignees (in terms of size of intellectual property portfolio). In addition, it includes a patent benchmarking analysis and detailed valuation analysis.
  • Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2014, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] type of partner, [D] generation of technology, [E] type of linker, [F] type of conjugation, [G] target therapeutic area(s), [H] most popular technologies, [I] most active players and [J] geographical location of the companies.
  • Business Model Analysis: An insightful analysis on business models adopted by various ADC technology providers engaged in this industry along with the information on parameters, such as [A] year of partnership, [B] purpose of partnership, [C] type of business strategy adopted (technology-out licensing, technology-in licensing, product out-licensing, product in-licensing, collaborative research and others), [D] type of investment, [E] amount invested and [F] most active players.
  • Likely Partner Analysis: A detailed evaluation of several antibody drug conjugate therapeutics developers that are most likely to collaborate with ADC linker and conjugation technology companies in the near future. This analysis considers various relevant parameters, including [A] developer strength (in terms of company size and its experience), [B] portfolio strength (based on type of linker and antibody structure), [C] pipeline strength (based on stage of development of a drug and number of pre-clinical molecules) and [D] therapeutic area.
  • Brand Positioning Analysis: An insightful brand positioning analysis of prominent antibody conjugation technology providers, highlighting the current perceptions regarding their proprietary technologies by taking into consideration several relevant aspects, such as [A] experience of the technology provider, [B] number of technologies offered, [C] product diversity, [D] number of patents and [E] number of partnerships.
  • Case Study: The report includes a case study discussing the overall landscape of the antibody drug conjugates market, based on a number of parameters, such as [A] stage of development, [B] target disease indication, [C] therapeutics area, [D] line of treatment, [E] dosing frequency, [F] type of therapy, [G] target antigen, [H] antibody isotype, [I] payload / cytotoxin / warhead, [J] payload type, [K] type of linker. Further, it highlights information on antibody drug conjugate developers, including details on [L] year of establishment, [M] company size and [N] location of headquarters and [N] most active players in this domain.

Key Questions Answered in this Report

  • How many companies are currently engaged in this market?
  • Which are the leading companies in this market?
  • What kind of partnership models are commonly adopted by industry stakeholders?
  • Which developers are most likely to collaborate with ADC linker and conjugation technology providers?
  • What factors are likely to influence the evolution of this market?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Additional Benefits

  • Complimentary PPT Insights Packs
  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 10% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

Table of Contents

1.               PREFACE
1.1.            Introduction
1.2.            Key Market Insights
1.3.            Scope of the Report
1.4.            Research Methodology
1.5.            Frequently Asked Questions
1.6.            Chapter Outlines

2.    EXECUTIVE SUMMARY
3.    INTRODUCTION
3.1.    Chapter Overview
3.2.     Antibody Drug Conjugates (ADCs)
3.2.1.    Components of ADCs
3.2.1.1.    Antibody
3.2.1.2.    Cytotoxin
3.2.1.3.    Linker
3.3.    Advantages of ADCs Over Conventional Therapeutics
3.4.    ADC Linker Technologies
3.4.1.    Non-cleavable Linkers
3.4.2.    Cleavable Linkers
3.4.    ADC Conjugation Technologies
3.4.1.    Chemical Conjugation
3.4.2.    Enzymatic Conjugation
3.5.    Future Perspectives

4.    ADC LINKER AND CONJUGATION TECHNOLOGIES: MARKET LANDSCAPE
4.1.    Chapter Overview
4.2.    ADC Linker and Conjugation Technologies: Overall Market Landscape
4.2.1.    Analysis by Type of Technology
4.2.2.    Analysis by Availability of Licensing
4.3.    ADC Conjugation Technologies
4.3.1.    Analysis by Generation of Technology
4.3.2.    Analysis by Site Specificity
4.3.3.    Analysis by Type of Conjugation
4.3.4.    Analysis by Drug Antibody Ratio
4.3.5.    Analysis by Compatible Linker
4.3.6.    Analysis by Conjugation Chemistry
4.3.7.    Analysis by Conjugation Site
4.4.    ADC Linker and ADC Linker-Payload Technologies
4.4.1.    Analysis by Type of Linker
4.5.    ADC Linker and Conjugation Technology Providers
4.5.1.    Analysis by Year of Establishment
4.5.2.    Analysis by Company Size
4.5.3.    Analysis by Location of Headquarters
4.5.4.    Analysis by Year of Establishment and Location of Headquarters
4.5.5.    Analysis by Company Size and Location of Headquarters
4.6.    ADC Conjugation Technologies Service Providers

5    TECHNOLOGY COMPETITIVENESS ANALYSIS
5.1.    Chapter Overview
5.2.    Assumptions and Key Parameters
5.3.    Methodology
5.4.    ADC Linker and Conjugation Technologies: Technology Competitiveness Analysis
5.4.1.    Technologies Offered by Small Companies
5.4.2.    Technologies Offered by Mid-sized Companies
5.4.3.    Technologies Offered by Large Companies

6.    COMPANY PROFILES
6.1.    Chapter Overview
6.2.    Companies Headquartered in North America
6.2.1.    Ambrx
6.2.1.2.    Company Overview
6.2.1.3.    Financial Information
6.2.1.4.    Technology Portfolio
6.2.1.5.    Recent Developments and Future outlook
6.2.2.    Catalent Biologics
6.2.2.1.    Company Overview
6.2.2.2.    Financial Information
6.2.2.3.    Technology Portfolio
6.2.2.4.    Recent Developments and Future outlook
6.2.3.    Mersana Therapeutics
6.2.3.1.    Company Overview
6.2.3.2.    Financial Information
6.2.3.3.    Technology Portfolio
6.2.3.4.    Recent Developments and Future outlook
6.2.4.    Seagen
6.2.4.1.    Company Overview
6.2.4.2.    Financial Information
6.2.4.3.    Technology Portfolio
6.2.4.4.    Recent Developments and Future outlook
6.2.5.    Sutro Biopharma
6.2.5.1.    Company Overview
6.2.5.2.    Financial Information
6.2.5.3.    Technology Portfolio
6.2.5.4.    Recent Developments and Future outlook
6.3.    Companies Headquartered in Europe
6.3.1.    Antikor
6.3.1.1.    Company Overview
6.3.1.2.    Technology Portfolio
6.3.1.3.    Recent Developments and Future outlook
6.3.2.    Iksuda Therapeutics
6.3.2.1.       Company Overview
6.3.2.2.    Technology Portfolio
6.3.2.3.    Recent Developments and Future outlook
6.3.3.    Heidelberg Pharma
6.3.3.1.    Company Overview
6.3.3.2.    Financial Information
6.3.3.3.    Technology Portfolio
6.3.3.4.    Recent Developments and Future outlook
6.3.4.    LinXis
6.3.4.1.    Company Overview
6.3.4.2.    Technology Portfolio
6.3.4.3.    Recent Developments and Future outlook
6.3.5.    NBE-Therapeutics
6.3.5.1.    Company Overview
6.3.5.2.    Technology Portfolio
6.3.5.3.    Recent Developments and Future outlook
6.4.    Companies Headquartered in Asia-Pacific and Rest of the World
6.4.1.    Alteogen
6.4.1.1.    Company Overview
6.4.1.2.    Technology Portfolio
6.4.1.3.    Recent Developments and Future outlook
6.5.2.    LegoChem Biosciences
6.5.2.1.    Company Overview
6.5.2.2.    Technology Portfolio
6.5.2.3.    Recent Developments and Future outlook

7.    PATENT ANALYSIS
7.1.    Chapter Overview
7.2.    Scope and Methodology
7.3.    ADC Linker and Conjugation Technologies: Patent Analysis
7.3.1.    Analysis by Publication Year
7.3.2.    Analysis by Application Year
7.3.3.    Analysis by Annual Number of Granted Patents and Patent Applications
7.3.4.    Analysis by Patent Jurisdiction
7.3.5.    Analysis by CPC Symbols and Sections
7.3.6.    Analysis by Type of Applicant
7.3.7.    Leading Industry Players: Analysis by Number of Patents
7.3.8.    Leading Non-Industry Players: Analysis by Number of Patents
7.3.9.    Leading Patent Assignees: Analysis by Number of Patents
7.4.    Patent Benchmarking Analysis
7.4.1.    Analysis by Patent Characteristics
7.5.    Patent Valuation
7.6.    Leading Patents by Number of Citations

8.    PARTNERSHIPS AND COLLABORATIONS
8.1.            Chapter Overview
8.2.            Partnership Models
8.3.    ADC Linker and Conjugation Technologies: Partnerships and Collaborations
8.3.1.    Analysis by Year of Partnership
8.3.2.    Analysis by Type of Partnership
8.3.3.    Analysis by Year of Partnership and Type of Partnership
8.3.4.    Analysis by Type of Partnership and Generation of Technology
8.3.5.    Analysis by Type of Partnership and Type of Linker
8.3.6.    Analysis by Type of Partnership and Type of Conjugation
8.3.7.    Analysis by Type of Partner
8.3.8.    Analysis by Year of Partnership and Type of Partner
8.3.9.    Analysis by Type of Partnership and Type of Partner
8.3.10.    Analysis by Target Therapeutic Area(s)
8.3.11.    Most Active Players: Analysis by Number of Partnerships
8.3.12.       Most Popular Technologies: Analysis by Number of Partnerships
8.4.           Regional Analysis
8.4.1.    Local and International Agreements
8.4.12.    Intercontinental and Intracontinental Agreements

9.               BUSINESS MODEL ANALYSIS
9.1.            Chapter Overview
9.2.             Business Strategies
9.3.            ADC Linker and Conjugation Technology Providers: Business Strategy Analysis
9.3.1.         Analysis by Purpose of Partnership
9.3.2.         Analysis by Year of Partnership and Purpose of Partnership
9.3.3.         Analysis by Type of Business Strategy Adopted
9.3.4.         Analysis by Purpose of Partnership and Type of Business Strategy Adopted
9.3.5.         Analysis by Upfront and Milestone Payments
9.3.6.         Analysis by Type of Business Strategy Adopted and Deal Value
9.4.        Most Active Players: Analysis by Number of Partnerships
9.4.1.         Synaffix
9.4.1.1.      Analysis by Purpose of Partnership
9.4.1.2.      Analysis of Technology Out-Licensing Deals by Deal Value
9.4.2.         LegoChem Biosciences
9.4.2.1.      Analysis by Purpose of Partnership
9.4.2.2.      Analysis by Year of Partnership and Business Strategy Adopted
9.4.2.3.      Analysis of Technology Out-Licensing Deals by Amount of Investment
9.4.3.         Catalent Biologics
9.4.3.1.      Analysis by Purpose of Partnership
9.4.3.2.      Analysis by Year of Partnership and Business Strategy Adopted
9.4.4.         Sutro Biopharma
9.4.4.1.      Analysis by Purpose of Partnership
9.4.4.2.      Analysis by Year of Partnership and Business Strategy Adopted
9.4.4.3.      Analysis of Technology Out-Licensing Deals by Deal Value
9.4.5.         Heidelberg Pharma
9.4.5.1.      Analysis by Purpose of Partnership
9.4.5.2.      Analysis by Year of Partnership and Business Strategy Adopted
9.4.6.         Mersana Therapeutics
9.4.6.1.      Analysis by Purpose of Partnership
9.4.6.2.      Analysis by Year of Partnership and Business Strategy Adopted
9.5.            Concluding Remarks

10.    LIKELY PARTNERS ANALYSIS
10.1.    Chapter Overview
10.2.    Assumptions / Key Parameters
10.3.    Scope and Methodology
10.4.    Potential Strategic Partners in North America
10.4.1.    Most Likely Partners
10.4.2.    Likely Partners
10.4.3.    Less Likely Partners
10.4.4.    Least Likely Partners
10.5.    Potential Strategic Partners in Europe
10.5.1.    Most Likely Partners
10.5.2.    Likely Partners
10.5.3.    Less Likely Partners
10.5.4.    Least Likely Partners
10.6.    Potential Strategic Partners in Asia-Pacific and Rest of the World
10.6.1.    Most Likely Partners
10.6.2.    Likely Partners
10.6.3.    Less Likely Partners
10.6.4.    Least Likely Partners

11.     BRAND POSITIONING ANALYSIS
11.1.          Chapter Overview
11.2.           Scope and Methodology
11.3.          Key Parameters
11.4.          Brand Positioning Matrix: ADC Conjugation Technology Providers
11.4.1.       Brand Positioning Matrix: Abzena
11.4.2.       Brand Positioning Matrix: Ambrx
11.4.3.       Brand Positioning Matrix: Byondis
11.4.4.       Brand Positioning Matrix: Creative Biolabs
11.4.5.       Brand Positioning Matrix: Eisai
11.4.6.       Brand Positioning Matrix: Mersana Therapeutics
11.4.7.       Brand Positioning Matrix: Sorrento Therapeutics
11.4.8.       Brand Positioning Matrix: Tubulis

12.     CASE STUDY: ANTIBODY DRUG CONJUGATES
12.1.       Chapter Overview
12.2.       Antibody Drug Conjugates: Therapies Pipeline
12.2.1.       Analysis by Stage of Development
12.2.2.       Analysis by Target Disease Indication(s)
12.2.3.       Analysis by Therapeutic Area(s)
12.2.4.       Analysis by Line of Treatment
12.2.5.       Analysis by Dosing Frequency
12.2.6.       Analysis by Type of Therapy
12.2.7.       Analysis by Target Antigen
12.2.8.       Analysis by Antibody Isotype
12.2.9.       Analysis by Type of Payload / Cytotoxin / Warhead
12.2.10.       Analysis by Type of Payload
12.2.11.       Analysis by Linker
12.2.12.       Analysis by Type of Linker (Cleavable / Non-Cleavable)
12.3.          Antibody Drug Conjugate: List of Developers
12.3.1.          Analysis by Year of Establishment
12.3.2.          Analysis by Company Size
12.3.3.          Analysis by Location of Headquarters
12.3.4.          Analysis by Company size and Location of Headquarters
12.3.5.          Most Active Players: Analysis by Number of Therapies

13.            MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1.     Chapter Overview
13.2.     Key Assumptions
13.3.    Forecast Methodology

13.4.     Global ADC Linker and Conjugation Technologies Market, Historical, Base and Forecasted Scenario, till 2035
13.4.1.    ADC Linker and Conjugation Technologies Market: Distribution by Generation of Technology, Current Year and 2035
13.4.1.1.    ADC Linker and Conjugation Technologies Market for Third-Generation     Technologies till 2035
13.4.1.2. ADC Linker and Conjugation Technologies Market for Second-Generation Technologies, till 2035
13.4.1.3.  ADC Linker and Conjugation Technologies Market for Next-Generation Technologies, till 2035
13.4.2.   ADC Linker and Conjugation Technologies Market: Distribution by Type of Conjugation, Current Year and 2035
13.4.2.1.    ADC Linker and Conjugation Technologies Market for Chemical Conjugation, till 2035
13.4.2.2.   ADC Linker and Conjugation Technologies Market for Chemoenzymatic Conjugation, till 2035
13.4.2.3.    ADC Linker and Conjugation Technologies Market for Enzymatic Conjugation
13.4.3.     ADC Linker and Conjugation Technologies Market: Distribution by Type of Linker, Current Year and 2035
13.4.3.1.   ADC Linker and Conjugation Technologies Market for Cleavable Linkers, till 2035
13.4.3.2.   ADC Linker and Conjugation Technologies Market for Non-Cleavable Linkers, till 2035
13.4.4.     ADC Linker and Conjugation Technologies Market: Distribution by Type of Payment Model Adopted, Current Year and 2035
13.4.4.1.   ADC Linker and Conjugation Technologies Market for Upfront Payments, till 2035
13.4.4.2.   ADC Linker and Conjugation Technologies Market for Milestone Payments, till 2035
13.4.5.     ADC Linker and Conjugation Technologies Market: Distribution by Key Geographical Regions, Current Year and 2035
13.4.5.1.    ADC Linker and Conjugation Technologies Market in North America, till 2035
13.4.5.1.1.    ADC Linker and Conjugation Technologies Market in North America: Distribution by Generation of Technology, till 2035
13.4.5.1.2.    ADC Linker and Conjugation Technologies Market in North America: Distribution by Type of Conjugation, till 2035
13.4.5.1.3.    ADC Linker and Conjugation Technologies Market in North America: Distribution by Type Linker, till 2035
13.4.5.2.    ADC Linker and Conjugation Technologies Market in Europe, till 2035
13.4.5.2.1.    ADC Linker and Conjugation Technologies Market in Europe: Distribution by Generation of Technology, till 2035
13.4.5.2.2. ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type of Conjugation, till 2035
13.4.5.2.3.    ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type Linker, till 2035
13.4.5.3.    ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World, till 2035
13.4.5.3.1.    ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Generation of Technology, till 2035
13.4.5.3.2.    ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Type of Conjugation, till 2035
13.4.5.3.3.    ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Type of Linker, till 2035
13.5.          Concluding Remarks

14.      EXECUTIVE INSIGHTS
14.1.          Chapter Overview
14.2.           Abzena
14.2.1.          Company Snapshot
14.2.2.       Interview Transcript: Saptarshi Ghosh (Scientist II)
14.3.           MedLink Therapeutics
14.3.1.          Company Snapshot
14.3.2.       Interview Transcript: Jiaqiang Cai (Co-Founder and Chief Scientific Officer)
14.4.           Merck KGaA
14.4.1.          Company Snapshot
14.4.2.       Interview Transcript: Kai Uhrig (Head of Strategy and Business Development)
14.5.           Singzyme
14.5.1.          Company Snapshot
14.5.2.       Interview Transcript: Cedric Lizin (Board Member)
14.6.           Ajinomoto
14.6.1.          Company Snapshot
14.6.2.       Interview Transcript: Okuzumi-Tatsuya (General Manager, Research and Development), Brian Mendelsohn (Director of ADC Process Development and Tech Transfer)
14.7.           Eucodis Bioscience
14.7.1.          Company Snapshot
14.7.2.       Interview Transcript: Jan Modregger (Head of Research and Development)
14.8.           NBE-Therapeutics
14.8.1.          Company Snapshot
14.8.2.       Interview Transcript: Wouter Verhoeven (Former Chief Business Officer)
14.9.           Shanghai Miracogen
14.9.1.          Company Snapshot
14.9.2.       Interview Transcript: Mary Chaohong Hu (Chief Executive Officer)
14.10.           Synaffix
14.10.1.     Company Snapshot
14.10.2.     Interview Transcript: Floris van Delft (Chief Scientific Officer)

15.      CONCLUDING REMARKS16.      APPENDIX 1: TABULATED DATA17.          APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 2.1    Executive Summary: Current Market Landscape of ADC Linker and Conjugation Technologies
Figure 2.2    Executive Summary: Patent Analysis
Figure 2.3    Executive Summary: Partnerships and Collaborations
Figure 2.4    Executive Summary: Business Model Analysis
Figure 2.5    Executive Summary: Case Study on ADC Therapeutics
Figure 2.6    Executive Summary: Market Sizing and Opportunity Analysis
Figure 3.1    Components of ADCs
Figure 3.2     Types of Linkers
Figure 4.1    ADC Linker and Conjugation Technologies: Distribution by Type of Technology
Figure 4.2        ADC Linker and Conjugation Technologies: Distribution by Availability of
Licensing
Figure 4.3        ADC Conjugation Technologies: Distribution by Generation of Technology
Figure 4.4        ADC Conjugation Technologies: Distribution by Site Specificity
Figure 4.5     ADC Conjugation Technologies: Distribution by Type of Conjugation
Figure 4.6     ADC Conjugation Technologies: Distribution by Drug Antibody Ratio
Figure 4.7        ADC Conjugation Technologies: Distribution by Compatible Linker
Figure 4.8        ADC Conjugation Technologies: Distribution by Conjugation Chemistry
Figure 4.9        ADC Conjugation Technologies: Distribution by Conjugation Site
Figure 4.10        ADC Linker and ADC Linker-Payload Technologies: Distribution by Type of Linker
Figure 4.11        ADC Linker and Conjugation Technology Providers: Distribution by Year of Establishment
Figure 4.12      ADC Linker and Conjugation Technology Providers: Distribution by Company Size
Figure 4.1.        ADC Linker and Conjugation Technology Providers: Distribution by Location of Headquarters
Figure 4.14        ADC Linker and Conjugation Technology Providers: Distribution by Year of Establishment and Location of Headquarters
Figure 4.15        ADC Linker and Conjugation Technology Providers: Distribution by Company Size and Location of Headquarters
Figure 5.1    Technology Competitiveness Analysis: Distribution of Technologies Offered by Small Companies
Figure 5.2    Technology Competitiveness Analysis: Distribution of Technologies Offered by Mid-sized Companies
Figure 5.3    Technology Competitiveness Analysis: Distribution of Technologies Offered by Large Companies
Figure 6.1     Ambrx: Annual Revenues, FY 2020 Onwards (USD Million)
Figure 6.2     Catalent Biologics: Revenues, FY 2018 Onwards (USD Billion)
Figure 6.3    Mersana Therapeutics: Annual Revenues, FY 2018 Onwards (USD Million)
Figure 6.4     Seagen: Revenues, FY 2018 Onwards (USD Billion)
Figure 6.5     Sutro Biopharma: Revenues, FY 2018 Onwards (USD Million)
Figure 6.6     Heidelberg Pharma: Annual Revenues, FY 2018 Onwards (EUR Million)
Figure 7.1    Patent Analysis: Distribution by Type of Patent
Figure 7.2    Patent Analysis: Cumulative Distribution by Publication Year
Figure 7.3    Patent Analysis: Cumulative Distribution by Application Year
Figure 7.4    Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications
Figure 7.5    Patent Analysis: Distribution by Patent Jurisdiction
Figure 7.6    Patent Analysis: Distribution by CPC Symbols and Sections
Figure 7.7    Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Figure 7.9    Leading Industry Players: Distribution by Number of Patents
Figure 7.10    Leading Non-Industry Players: Distribution by Number of Patents
Figure 7.11    Leading Patent Assignees: Distribution by Number of Patents
Figure 7.12     Patent Benchmarking Analysis: Distribution of Leading Industry Player by Patent Characteristics (CPC Codes)
Figure 7.13    Patent Analysis: Distribution by Patent Age
Figure 7.14    ADC Linker and Conjugation Technologies: Patent Valuation
Figure 8.1     Partnerships and Collaborations: Distribution by Year of Partnership
Figure 8.2     Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3     Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Figure 8.4     Partnerships and Collaborations: Distribution by Type of Partnership and Generation of Technology
Figure 8.5     Partnerships and Collaborations: Distribution by Type of Partnership and Type of Linker
Figure 8.6    Partnerships and Collaborations: Distribution by Type of Partnership and Type of Conjugation
Figure 8.7     Partnerships and Collaborations: Distribution by Type of Partner
Figure 8.8     Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 8.9     Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 8.10     Partnerships and Collaborations: Distribution by Therapeutic Area(s)
Figure 8.11    Most Active Players: Distribution by Number of Partnerships
Figure 8.12    Most Popular Technologies: Distribution by Number of Partnerships
Figure 8.13    Partnerships and Collaborations: Local and International Agreements
Figure 8.14    Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 9.1     Business Models Analysis: Distribution by Purpose of Partnership
Figure 9.2     Business Models Analysis: Year-wise Distribution by Purpose of Partnership
Figure 9.3     Business Models Analysis: Distribution by Type of Business Strategy Adopted
Figure 9.4     Business Models Analysis: Distribution by Purpose of Partnership and Type of Business Strategy Adopted
Figure 9.5     Business Models Analysis: Distribution by Upfront and Milestone Payments
Figure 9.6    Business Models Analysis: Distribution by Type of Business Strategy Adopted and Deal Value
Figure 9.7    Synaffix: Distribution by Purpose of Partnership
Figure 9.8     Synaffix: Distribution of Technology Out-Licensing Deals by Deal Value
Figure 9.9     LegoChem Biosciences: Distribution by Purpose of Partnership
Figure 9.10     LegoChem Biosciences: Distribution by Year of Partnership and Business Strategy Adopted
Figure 9.11     LegoChem Biosciences: Distribution of Technology Out-Licensing Deals by Deal Value
Figure 9.12     Catalent Biologics: Distribution by Purpose of Partnership
Figure 9.13     Catalent Biologics: Distribution by Year of Partnership and Business Strategy Adopted
Figure 9.14     Sutro Biopharma: Distribution by Purpose of Partnership
Figure 9.15     Sutro Biopharma: Distribution by Year of Partnership and Business Strategy Adopted
Figure 9.16     Sutro Biopharma:  Distribution of Technology Out-Licensing Deals by Deal Value
Figure 9.17     Heidelberg Pharma: Distribution by Purpose of Partnership
Figure 9.18     Heidelberg Pharma: Distribution by Year of Partnership and Business Strategy Adopted
Figure 9.19     Mersana Therapeutics: Distribution by Purpose of Partnership
Figure 9.20     Mersana Therapeutics: Distribution by Year of Partnership and Business Strategy Adopted
Figure 11.1     Brand Positioning Analysis: Competitive Advantage
Figure 11.2     Brand Positioning Analysis: Reasons to Believe
Figure 11.3     Brand Positioning Matrix: Abzena
Figure 11.4     Brand Positioning Matrix: Ambrx
Figure 11.5     Brand Positioning Matrix: Byondis
Figure 11.6.    Brand Positioning Matrix: Creative Biolabs
Figure 11.7     Brand Positioning Matrix: Eisai
Figure 11.8     Brand Positioning Matrix: Mersana Therapeutics
Figure 11.9     Brand Positioning Matrix: Sorrento Therapeutics
Figure 11.10     Brand Positioning Matrix: Tubulis
Figure 12.1    Antibody Drug Conjugates: Distribution by Stage of Development
Figure 12.2    Antibody Drug Conjugates: Distribution by Target Disease Indication(s)
Figure 12.3    Antibody Drug Conjugates: Distribution by Therapeutic Area(s)
Figure 12.4    Antibody Drug Conjugates: Distribution by Line of Treatment
Figure 12.5     Antibody Drug Conjugates: Distribution by Dosing Frequency
Figure 12.6     Antibody Drug Conjugates: Distribution by Type of Therapy
Figure 12.7    Antibody Drug Conjugates: Distribution by Target Antigen
Figure 12.8    Antibody Drug Conjugates: Distribution by Antibody Isotype
Figure 12.9    Antibody Drug Conjugates: Distribution by Type of Payload / Cytotoxin / Warhead
Figure 12.10        Antibody Drug Conjugates: Distribution by Type of Payload
Figure 12.11        Antibody Drug Conjugates: Distribution by Linker
Figure 12.12    Antibody Drug Conjugates: Distribution by Type of Linker
Figure 12.13        Antibody Drug Conjugate Developers: Distribution by Year of Establishment
Figure 12.14        Antibody Drug Conjugates Developers: Distribution by Company Size
Figure 12.15        Antibody Drug Conjugates Developers: Distribution by Location of Headquarters
Figure 12.16        Antibody Drug Conjugates Developers: Distribution by Company Size and Location of Headquarters
Figure 12.17        Most Active Players: Distribution by Number of Therapies
Figure 13.1    Licensing Agreements: Distribution of Financial Components
Figure 13.2    Technology Licensing Deal: Payment Structure
Figure 13.3    Global ADC Linker and Conjugation Technologies Market, Historical, Base and Forecasted Scenario, till 2035 (USD Million)
Figure 13.4    ADC Linker and Conjugation Technologies Market: Distribution by Generation of Technology, Current Year and 2035
Figure 13.5    ADC Linker and Conjugation Technologies Market for Third-Generation Technologies, till 2035 (USD Million)
Figure 13.6    ADC Linker and Conjugation Technologies Market for Second-Generation Technologies, till 2035 (USD Million)
Figure 13.7    ADC Linker and Conjugation Technologies Market for Next-Generation Technologies, till 2035 (USD Million)
Figure 13.8    ADC Linker and Conjugation Technologies Market: Distribution by Type of Conjugation, Current Year and 2035
Figure 13.9    ADC Linker and Conjugation Technologies Market for Chemical Conjugation, till 2035 (USD Million)
Figure 13.10    ADC Linker and Conjugation Technologies Market for Chemoenzymatic Conjugation, till 2035 (USD Million)
Figure 13.11    ADC Linker and Conjugation Technologies Market for Enzymatic Conjugation, till 2035 (USD Million)
Figure 13.12    ADC Linker and Conjugation Technologies Market: Distribution by Type of Linker, Current Year and 2035
Figure 13.13    ADC Linker and Conjugation Technologies Market for Cleavable Linkers, till 2035 (USD Million)
Figure 13.14    ADC Linker and Conjugation Technologies Market for Non-Cleavable Linkers, till 2035 (USD Million)
Figure 13.15    ADC Linker and Conjugation Technologies Market: Distribution by Type of Payment Model Adopted, Current Year and 2035
Figure 13.16    ADC Linker and Conjugation Technologies Market for Upfront Payments, till 2035 (USD Million)
Figure 13.17    ADC Linker and Conjugation Technologies Market for Milestone Payments, till 2035 (USD Million)
Figure 13.18    ADC Linker and Conjugation Technologies Market: Distribution by Key Geographical Regions, Current Year and 2035
Figure 13.19    ADC Linker and Conjugation Technologies Market in North America, till 2035 (USD Million)
Figure 13.20    ADC Linker and Conjugation Technologies Market in North America: Distribution   by Generation of Technology, till 2035 (USD Million)
Figure 13.21    ADC Linker and Conjugation Technologies Market in North America: Distribution by Type of Conjugation, till 2035 (USD Million)
Figure 13.22    ADC Linker and Conjugation Technologies Market in North America: Distribution by Type Linker, till 2035 (USD Million)
Figure 13.23    ADC Linker and Conjugation Technologies Market in Europe, till 2035 (USD Million)
Figure 13.24    ADC Linker and Conjugation Technologies Market in Europe: Distribution by Generation of     Technology, till 2035 (USD Million)
Figure 13.25    ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type of Conjugation, till 2035 (USD Million)
Figure 13.26    ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type Linker, till 2035 (USD Million)
Figure 13.27    ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World, till 2035 (USD Million)
Figure 13.28    ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Generation of Technology, till 2035 (USD Million)
Figure 13.29    ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Type of Conjugation, till 2035 (USD Million)
Figure 13.30    ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Type Linker, till 2035 (USD Million)
Figure 15.1    Concluding Remarks: Current Market Landscape of ADC Linker and Conjugation Technologies
Figure 15.2    Concluding Remarks: Current Market Landscape of ADC Linker and Conjugation Technology Providers
Figure 15.3    Concluding Remarks: Patent Analysis
Figure 15.4    Concluding Remarks: Partnerships and Collaborations
Figure 15.5    Concluding Remarks: Business Model Analysis
Figure 15.6    Concluding Remarks: Case Study on Antibody Drug Conjugates
Figure 15.7    Concluding Remarks: Market Sizing and Opportunity Analysis
LIST OF TABLES
Table 3.1    Commonly Used Cytotoxins in ADC Therapeutics
Table 3.2         OEL Bands: Guidelines by SafeBridge Consultants
Table 4.1    ADC Linker and Conjugation Technologies: Overall Market Landscape
Table 4.2    ADC Conjugation Technologies: Information on Generation of Technology, Site-Specificity, Type of Conjugation and Drug Antibody Ratio
Table 4.3    ADC Conjugation Technologies: Information on Number of Steps Involved, Compatible Linker, Conjugation Chemistry and Conjugation Site
Table 4.4    ADC Linker and Linker-Payload Technologies: Information on Type of Linker and Linker Name
Table 4.5    ADC Linker and Conjugation Technology Providers
Table 4.6    ADC Conjugation Technologies Service Providers
Table 6.1     ADC Linkers and Conjugation Technologies: List of Profiled Companies
Table 6.2     Ambrx: Company Overview
Table 6.3    Ambrx: ADC Linkers and Conjugation Technologies Portfolio
Table 6.4    Ambrx: Antibody Drug Conjugates Portfolio
Table 6.5    Ambrx: Recent Developments and Future Outlook
Table 6.6    Catalent Biologics: Company Overview
Table 6.7    Catalent Biologics: ADC Linkers and Conjugation Technologies Portfolio
Table 6.8    Catalent Biologics: Antibody Drug Conjugates Portfolio
Table 6.9    Catalent Biologics: Recent Developments and Future Outlook
Table 6.10    Mersana Therapeutics: Company Overview
Table 6.11    Mersana Therapeutics: ADC Linkers and Conjugation Technologies Portfolio
Table 6.12    Mersana Therapeutics: Antibody Drug Conjugates Portfolio
Table 6.13    Mersana Therapeutics: Recent Developments and Future Outlook
Table 6.14    Seagen: Company Overview
Table 6.15    Seagen: ADC Linkers and Conjugation Technologies Portfolio
Table 6.16    Seagen: Antibody Drug Conjugates Portfolio
Table 6.17    Seagen: Recent Developments and Future Outlook
Table 6.18    Sutro Biopharma: Company Overview
Table 6.19    Sutro Biopharma: ADC Linkers and Conjugation Technologies Portfolio
Table 6.20    Sutro Biopharma: Antibody Drug Conjugates Portfolio
Table 6.21.    Sutro Biopharma: Recent Developments and Future Outlook
Table 6.22    Antikor: Company Overview
Table 6.23    Antikor: ADC Conjugation Technology Portfolio
Table 6.24    Antikor: Antibody Drug Conjugates Portfolio
Table 6.25    Antikor: Recent Developments and Future Outlook
Table 6.26    Iksuda Therapeutics: Company Overview
Table 6.27    Iksuda Therapeutics: ADC Linkers and Conjugation Technologies Portfolio
Table 6.28    Iksuda Therapeutics: Antibody Drug Conjugates Portfolio
Table 6.29    Heidelberg Pharma: Company Overview
Table 6.30    Heidelberg Pharma: ADC Linkers and Conjugation Technologies Portfolio
Table 6.31    Heidelberg Pharma: Antibody Drug Conjugates Portfolio
Table 6.32    Heidelberg Pharma: Recent Developments and Future Outlook
Table 6.33    LinXis: Company Overview
Table 6.34    LinXis: ADC Conjugation Technology Portfolio
Table 6.35    NBE-Therapeutics: Company Overview
Table 6.36    NBE-Therapeutics: ADC Linkers and Conjugation Technologies Portfolio
Table 6.37    NBE-Therapeutics: Antibody Drug Conjugates Portfolio
Table 6.38    Alteogen: Company Overview
Table 6.39    Alteogen: ADC Linkers and Conjugation Technologies Portfolio
Table 6.40    Alteogen: Antibody Drug Conjugates Portfolio
Table 6.41    LegoChem Biosciences: Company Overview
Table 6.42    LegoChem Biosciences: ADC Linkers and Conjugation Technologies Portfolio
Table 6.43    LegoChem Biosciences: Antibody Drug Conjugates Portfolio
Table 6.44    LegoChem Biosciences: Recent Developments and Future Outlook
Table 7.1    Patent Analysis: Top CPC Sections
Table 7.2     Patent Analysis: Top CPC Symbols
Table 7.3    Patent Analysis: Top CPC Codes
Table 7.4     Patent Analysis: Summary of Benchmarking Analysis
Table 7.5    Patent Analysis: Categorization based on Weighted Valuation Scores
Table 7.6    Patent Portfolio: List of Leading Patents (by Number of Citations)
Table 8.1    ADC Linker and Conjugation Technologies: Partnerships and Collaborations
Table 8.2    ADC Linker and Conjugation Technologies: Partnerships and Collaborations, Information on Type of Partner, Therapeutic Area(s) and Type of Agreement (Region-wise and Geography-wise)
Table 9.1    ADC Linker and Conjugation Technologies: Business Model Analysis
Table 10.1    North America: Most Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.2    North America: Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.3    North America: Less Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.4    North America: Least Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.5    Europe: Most Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.6    Europe: Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.7    Europe: Less Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.8    Europe: Least Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.9    Asia-Pacific and Rest of the World: Most Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.10    Asia-Pacific and Rest of the World: Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.11    Asia-Pacific and Rest of the World: Less Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.12    Asia-Pacific and Rest of the World: Least Likely Partners for ADC Linker and Conjugation Technology Providers
Table 12.1    Antibody Drug Conjugates: Information on Drug Candidates, Developer(s), Stage of Development, Target Disease Indication(s) and Therapeutics Area(s)
Table 12.2    Antibody Drug Conjugates: Information on Drug Candidates, Line of Treatment, Dosage Frequency, Type of Therapy, Target Antigen and Antibody Isotype
Table 12.3     Antibody Drug Conjugates: Information on Drug Candidates, Payload / Cytotoxin / Warhead, Type of Payload, Linker and Type of Linker (Cleavable and Non-Cleavable)
Table 12.4    Antibody Drug Conjugate Developers: Information on Year of Establishment, Company Size, Location of Headquarters
Table 13.1    Technology Licensing Deal: Tranches of Milestone Payments
Table 13.2    ADC Linker and Conjugation Technologies: Average Upfront Payments and Average Milestone Payments (USD Million)
Table 14.1    Abzena: Company Snapshot
Table 14.2    MedLink Therapeutics: Company Snapshot
Table 14.3    Merck KGaA: Company Snapshot
Table 14.4    Singzyme: Company Snapshot
Table 14.5    Ajinomoto: Company Snapshot
Table 14.6    Eucodis Bioscience: Company Snapshot
Table 14.7    Shanghai Miracogen: Company Snapshot
Table 14.8    NBE-Therapeutics: Company Snapshot
Table 14.9     Synaffix: Company Snapshot
Table 16.1    ADC Linker and Conjugation Technologies: Distribution by Type of Technology
Table 16.2    ADC Linker and Conjugation Technologies: Distribution by Availability of Licensing
Table 16.3    ADC Conjugation Technologies: Distribution by Generation of Technology
Table 16.4    ADC Conjugation Technologies: Distribution by Site Specificity
Table 16.5    ADC Conjugation Technologies: Distribution by Type of Conjugation
Table 16.6    ADC Conjugation Technologies: Distribution by Drug Antibody Ratio
Table 16.7    ADC Conjugation Technologies: Distribution by Compatible Linker
Table 16.8    ADC Conjugation Technologies: Distribution by Conjugation Chemistry
Table 16.9    ADC Conjugation Technologies: Distribution by Conjugation Site
Table 16.10    ADC Linker and ADC Linker-Payload Technologies: Distribution by Type of Linker
Table 16.11    ADC Linker and Conjugation Technology Providers: Distribution by Year of Establishment
Table 16.12    ADC Linker and Conjugation Technology Providers: Distribution by Company Size
Table 16.13    ADC Linker and Conjugation Technology Providers: Distribution by Location of Headquarters
Table 16.14    ADC Linker and Conjugation Technology Providers: Distribution by Year of Establishment and Location of Headquarters
Table 16.15    ADC Linker and Conjugation Technology Providers: Distribution by Company Size and Location of Headquarters
Table 16.16    Ambrx: Annual Revenues, FY 2020 Onwards (USD Million)
Table 16.17    Mersana Therapeutics: Annual Revenues, FY 2018 Onwards (USD Million)
Table 16.18    Seagen: Revenues, FY 2018 Onwards (USD Billion)
Table 16.19    Sutro Biopharma: Revenues, FY 2018 Onwards (USD Million)
Table 16.20    Heidelberg Pharma: Annual Revenues, FY 2018 Onwards (EUR Million)
Table 16.21    Catalent Biologics: Revenues, FY 2018 Onwards (USD Billion)
Table 16.22    Patent Analysis: Distribution by Type of Patent
Table 16.23    Patent Analysis: Cumulative Distribution by Publication Year
Table 16.24    Patent Analysis: Cumulative Distribution by Application Year
Table 16.25    Patent Analysis: Distribution by Patent Type and Publication Year
Table 16.26    Patent Analysis: Distribution by Patent Jurisdiction
Table 16.27    Patent Analysis: Distribution by CPC Symbols and Sections
Table 16.28    Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Table 16.29    Leading Industry Players: Distribution by Number of Patents
Table 16.30    Leading Non-Industry Players: Distribution by Number of Patents
Table 16.31    Leading Individual Assignees: Distribution by Number of Patents
Table 16.32    Patent Benchmarking Analysis: Distribution of Leading Industry Player by Patent Characteristics (CPC Codes)
Table 16.33    Patent Analysis: Distribution by Patent Age
Table 16.34    ADC Linker and Conjugation Technologies: Patent Valuation
Table 16.35    Partnerships and Collaborations: Distribution by Year of Partnership
Table 16.36    Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.37    Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Table 16.38    Partnerships and Collaborations: Distribution by Type of Partnership and Generation of Technology
Table 16.39    Partnerships and Collaborations: Distribution by Type of Partnership and Type of Linker
Table 16.40    Partnerships and Collaborations: Distribution by Type of Partnership and Type of Conjugation
Table 16.41    Partnerships and Collaborations: Distribution by Type of Partner
Table 16.42    Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 16.43    Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 16.44    Partnerships and Collaborations: Distribution by Therapeutic Area(s)
Table 16.45    Most Active Players: Distribution by Number of Partnerships
Table 16.46    Most Popular Technologies: Distribution by Number of Partnerships
Table 16.47    Partnership and Collaborations: Local and International Agreements
Table 16.48    Partnerships and Collaborations: Intercontinental and Intracontinental     Agreements
Table 16.49    Business Models Analysis: Distribution by Purpose of Partnership
Table 16.50    Business Models Analysis: Distribution by Year of Partnership and Purpose of Partnership
Table 16.51    Business Models Analysis: Distribution by Type of Business Strategy Adopted
Table 16.52    Business Models Analysis: Distribution by Purpose of Partnership and Type of Business Strategy Adopted
Table 16.53    Business Models Analysis: Distribution by Upfront and Milestone Payments
Table 16.54    Business Models Analysis: Distribution by Type of Business Model Adopted and Deal Value
Table 16.55    Synaffix: Distribution by Purpose of Partnership
Table 16.56    Synaffix: Technology Out-Licensing Deals by Deal Value
Table 16.57    LegoChem Biosciences: Distribution by Purpose of Partnership
Table 16.58    LegoChem Biosciences: Distribution by Year of Partnership and Business Strategy Adopted
Table 16.59    LegoChem Biosciences: Distribution of Technology Out-Licensing Deals by Deal Value
Table 16.60    Catalent Biologics: Distribution by Purpose of Partnership
Table 16.61    Catalent Biologics: Distribution by Year of Partnership and Business Strategy Adopted
Table 16.62    Sutro Biopharma: Distribution by Purpose of Partnership
Table 16.63     Sutro Biopharma: Distribution by Year of Partnership and Business Strategy Adopted
Table 16.64     Sutro Biopharma:  Distribution of Technology Out-Licensing Deals by Deal Value
Table 16.65     Heidelberg Pharma: Distribution by Purpose of Partnership
Table 16.66     Heidelberg Pharma: Distribution by Year of Partnership and Business Strategy Adopted
Table 16.67     Mersana Therapeutics: Distribution by Purpose of Partnership
Table 16.68     Mersana Therapeutics: Distribution by Year of Partnership and Business Strategy Adopted
Table 16.69    Antibody Drug Conjugates: Distribution by Stage of Development
Table 16.70    Antibody Drug Conjugates: Distribution by Target Disease Indication
Table 16.71    Antibody Drug Conjugates: Distribution by Therapeutic Area(s)
Table 16.72    Antibody Drug Conjugates: Distribution by Line of Treatment
Table 16.73     Antibody Drug Conjugates: Distribution by Dosing Frequency
Table 16.74     Antibody Drug Conjugates: Distribution by Type of Therapy
Table 16.75    Antibody Drug Conjugates: Distribution by Target Antigen
Table 16.76    Antibody Drug Conjugates: Distribution by Antibody Isotype
Table 16.77    Antibody Drug Conjugates: Distribution by Type of Cytotoxin / Warhead
Table 16.78    Antibody Drug Conjugates: Distribution by Type of Payload
Table 16.79    Antibody Drug Conjugates: Distribution by Linker
Table 16.80    Antibody Drug Conjugates: Distribution by Type of Linker
Table 16.81    Antibody Drug Conjugate Developers: Distribution by Year of Establishment
Table 16.82    Antibody Drug Conjugates Developers: Distribution by Company Size
Table 16.83    Antibody Drug Conjugates Developers: Distribution by Location of Headquarters
Table 16.84    Antibody Drug Conjugates Developers: Distribution by Company Size and Location of Headquarters
Table 16.85    Most Active Players: Distribution by Number of Antibody Drug Conjugates
Table 16.86    Global ADC Linker and Conjugation Technologies Market, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 16.87    ADC Linker and Conjugation Technologies Market: Distribution by Generation of Technology, Current Year and 2035
Table 16.88    ADC Linker and Conjugation Technologies Market for Third-Generation Technologies, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.89    ADC Linker and Conjugation Technologies Market for Second-Generation Technologies, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.90    ADC Linker and Conjugation Technologies Market for Next-Generation Technologies, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.91    ADC Linker and Conjugation Technologies Market: Distribution by Type of Conjugation, Current Year and 2035
Table 16.92    ADC Linker and Conjugation Technologies Market for Chemical Conjugation, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.93    ADC Linker and Conjugation Technologies Market for Chemoenzymatic Conjugation, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.94    ADC Linker and Conjugation Technologies Market for Enzymatic Conjugation, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.95    ADC Linker and Conjugation Technologies Market: Distribution by Type of Linker, Current Year and 2035
Table 16.96    ADC Linker and Conjugation Technologies Market for Cleavable Linkers, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.97    ADC Linker and Conjugation Technologies Market for Non-Cleavable Linkers, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.98    ADC Linker and Conjugation Technologies Market: Distribution by Type of Payment Model Adopted, Current Year and 2035
Table 16.99    ADC Linker and Conjugation Technologies Market for Upfront Payments, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.100    ADC Linker and Conjugation Technologies Market for Milestone Payments, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.101    ADC Linker and Conjugation Technologies Market: Distribution by Key Geographical Regions, Current Year and 2035
Table 16.102    ADC Linker and Conjugation Technologies Market in North America, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.103    ADC Linker and Conjugation Technologies Market in North America: Distribution by Generation of Technology, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.104    ADC Linker and Conjugation Technologies Market in North America: Distribution by Type of Conjugation, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.105    ADC Linker and Conjugation Technologies Market in North America: Distribution by Type Linker till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.106    ADC Linker and Conjugation Technologies Market in Europe, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.107    ADC Linker and Conjugation Technologies Market in Europe: Distribution by Generation of Technology, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.108    ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type of Conjugation, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.109    ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type Linker till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.110    ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.111    ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Generation of Technology, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.112    ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Type of Conjugation, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.113    ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Type Linker till 2035, Conservative, Base and Optimistic Scenarios (USD Million)

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Alteogen
  • Ambrx
  • Antikor
  • Catalent Biologics
  • Heidelberg Pharma
  • Iksuda Therapeutics
  • LegoChem Biosciences
  • Mersana Therapeutics
  • NBE-Therapeutics
  • Seattle Genetics
  • Sutro Biopharma

Methodology

 

 

Loading
LOADING...

Related Topics

Related Reports

ADC Contract Manufacturing Market Industry Trends and Global Forecasts to 2035, by Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody Origin, Antibody Isotype, Type of Payload, Type of Linker and Key Geographical Regions - Product Image

ADC Contract Manufacturing Market Industry Trends and Global Forecasts to 2035, by Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody Origin, Antibody Isotype, Type of Payload, Type of Linker and Key Geographical Regions

  • Report
  • 510 Pages
  • Global
From
Antibody-drug Conjugates for Tumors Market - Global Forecast 2025-2030 - Product Image

Antibody-drug Conjugates for Tumors Market - Global Forecast 2025-2030

  • Report
  • 192 Pages
  • Global
From
Antibody Drug Conjugate Market - Global Forecast 2025-2032 - Product Image

Antibody Drug Conjugate Market - Global Forecast 2025-2032

  • Report
  • 186 Pages
  • Global
From
Antibody Drug Conjugate Market Industry Trends and Global Forecasts to 2035, by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens and Key Geographical Regions - Product Image

Antibody Drug Conjugate Market Industry Trends and Global Forecasts to 2035, by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens and Key Geographical Regions

  • Report
  • 716 Pages
  • Global
From
Antibody Drug Conjugate - Competitive Landscape, 2025 - Product Image

Antibody Drug Conjugate - Competitive Landscape, 2025

  • Report
  • 450 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.